Achieve Life Sciences (NASDAQ:ACHV) Stock Passes Above Two Hundred Day Moving Average of $4.40

Achieve Life Sciences, Inc. (NASDAQ:ACHV)’s stock price passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $4.40 and traded as high as $4.58. Achieve Life Sciences shares last traded at $4.38, with a volume of 63,124 shares trading hands.

Analyst Ratings Changes

ACHV has been the subject of a number of research reports. Oppenheimer reissued an “outperform” rating and issued a $18.00 target price on shares of Achieve Life Sciences in a report on Monday, April 1st. Lake Street Capital lowered their price target on shares of Achieve Life Sciences from $19.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, March 5th. Finally, Jonestrading began coverage on Achieve Life Sciences in a research report on Wednesday. They set a “buy” rating and a $20.00 price objective on the stock.

Achieve Life Sciences Price Performance

The stock has a 50-day moving average price of $4.42 and a 200-day moving average price of $4.40. The company has a debt-to-equity ratio of 4.02, a current ratio of 0.82 and a quick ratio of 0.82. The company has a market capitalization of $156.53 million, a P/E ratio of -2.99 and a beta of 1.32.

Hedge Funds Weigh In On Achieve Life Sciences

A number of hedge funds have recently bought and sold shares of the company. Tower Research Capital LLC TRC raised its position in shares of Achieve Life Sciences by 75.6% in the 1st quarter. Tower Research Capital LLC TRC now owns 3,646 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 1,570 shares in the last quarter. HRT Financial LP bought a new stake in Achieve Life Sciences in the fourth quarter worth approximately $32,000. Morgan Stanley lifted its stake in Achieve Life Sciences by 437.4% in the fourth quarter. Morgan Stanley now owns 13,547 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 11,026 shares during the period. Madison Park Capital Advisors LLC bought a new position in shares of Achieve Life Sciences during the 4th quarter worth approximately $41,000. Finally, Prelude Capital Management LLC bought a new position in shares of Achieve Life Sciences during the 2nd quarter worth approximately $49,000. Institutional investors own 33.52% of the company’s stock.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.